a public good project by the
Synthesis
Company
of California

© 2026

Michael Citron | doi.page

0 works0 citations0 h-index

Michael Citron

Merck & Co., Inc., Rahway, NJ, USA (United States)(US)

Publications by Year

Research Areas

Respiratory viral infections research, HIV Research and Treatment, Immune Cell Function and Interaction, Influenza Virus Research Studies, Viral gastroenteritis research and epidemiology

Most-Cited Works

→ Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys(2004)314 cited
→ Vaccine-Induced Cellular Immune Responses Reduce Plasma Viral Concentrations after Repeated Low-Dose Challenge with Pathogenic Simian Immunodeficiency Virus SIVmac239(2006)250 cited
→ Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge(2010)214 cited
→ Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection(2014)199 cited
→ Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection(2020)180 cited
→ A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein(2019)144 cited

→ Vaccine-Induced Cellular Responses Control Simian Immunodeficiency Virus Replication after Heterologous Challenge(2009)124 cited

→ Enhancement of α-Helicity in the HIV-1 Inhibitory Peptide DP178 Leads to an Increased Affinity for Human Monoclonal Antibody 2F5 but Does Not Elicit Neutralizing Responses in Vitro(2002)118 cited

→ HIV-1 Vaccine Development: Constrained Peptide Immunogens Show Improved Binding to the Anti-HIV-1 gp41 MAb(2003)101 cited

→ Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys(2009)83 cited